title: [Ofloxacin-cycloserine-protionamide-INH combination against treatment refractory lung tuberculosis].
abstract: Multiresistant tuberculoses are on the increase. The conversion rates in "additional" therapy are only modest. 17 multiresistant patients and 6 treatment-refractory tuberculoses were treated by us with ofloxacin-cycloserin-protionamide-INH. 16 of these patients were HIV positive. 21 patients converted after 3 months of treatment by the latest. 3 patients died of HIV syndrome. There was otherwise no difference between HIV positive and HIV negative patients. As a rule, the combination was well tolerated. In multiresistant tuberculosis, it is mandatory to administer at least 3 drugs to which there is no resistance.
authors.affiliation: Sanatorium Gishari, Ruanda.
authors.forename: F
authors.initials: F
authors.lastname: Mühlberger
authors.forename: F
authors.initials: F
authors.lastname: Nturanye
authors.forename: J
authors.initials: J
authors.lastname: Nasbimana
authors.forename: F
authors.initials: F
authors.lastname: Portaels
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000328:Adult; D003523:Cycloserine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage* / Q000009:adverse effects; D011515:Prothionamide / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D013183:Sputum / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D011515:Prothionamide; D003523:Cycloserine; D015242:Ofloxacin; D007538:Isoniazid
vernacular_title: Ofloxacin-Cycloserin-Protionamid-INH-Kombination gegen therapieresistente Lungentuberkulose.